Related Experiment Video
Updated: Nov 11, 2025

DNA Virus Detection System Based on RPA-CRISPR/Cas12a-SPM and Deep Learning
Published on: May 10, 2024
A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses
Xueqiu Lin1, Yanxia Liu1, Augustine Chemparathy1,2
1Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, called prophylactic antiviral CRISPR in human cells (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus. Here, we expand in silico analysis to use PAC-MAN to target a broad spectrum of human- or livestock-infectious RNA viruses with high specificity, coverage, and predicted efficiency. Our analysis reveals that a minimal set of 14 CRISPR RNAs (crRNAs) is able to target >90% of human-infectious viruses across 10 RNA virus families. We predict that a set of 5 experimentally validated crRNAs can target new SARS-CoV-2 variant sequences with zero mismatches. We also build an online resource (crispr-pacman.stanford.edu) to support community use of CRISPR-Cas13 for broad-spectrum RNA virus targeting. Our work provides a new bioinformatic resource for using CRISPR-Cas13 to target diverse RNA viruses to facilitate the development of CRISPR-based antivirals.
Insights
A new bioinformatic analysis shows that the prophylactic antiviral CRISPR in human cells (PAC-MAN) system can target over 90% of human infectious RNA viruses. This CRISPR-based antiviral strategy shows promise for broad-spectrum RNA virus targeting.
Area of Science:
- Molecular Biology
- Virology
- Bioinformatics
Background:
- The COVID-19 pandemic highlights the urgent need for broad-spectrum antiviral strategies.
- The CRISPR-Cas13 system, PAC-MAN, has previously shown potential against SARS-CoV-2 and influenza A virus.
Purpose of the Study:
- To computationally assess the potential of PAC-MAN for targeting a wide range of human and livestock RNA viruses.
- To identify a minimal set of CRISPR RNAs (crRNAs) for broad-spectrum viral targeting.
- To develop a community resource for CRISPR-Cas13 antiviral applications.
Main Methods:
- Extensive in silico analysis of PAC-MAN's targeting capabilities across diverse RNA viruses.
- Bioinformatic prediction of crRNA efficiency, specificity, and coverage.
- Development of an online resource for CRISPR-Cas13 antiviral research.
Main Results:
- A minimal set of 14 crRNAs can target over 90% of human-infectious viruses across 10 RNA virus families.
- A smaller set of 5 crRNAs is predicted to target new SARS-CoV-2 variants with high accuracy.
- An online resource (crispr-pacman.stanford.edu) is now available for researchers.
Conclusions:
- CRISPR-Cas13, via the PAC-MAN system, offers a promising bioinformatic resource for broad-spectrum RNA virus targeting.
- This approach facilitates the development of novel CRISPR-based antiviral therapies.
- The identified crRNAs and online tool can accelerate research into combating diverse viral threats.
Related Concept Videos
CRISPR
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
CRISPR/Cas9 Genome Editing
The Antiviral System of Bacteria and Archaea: CRISPR
Homologous Recombination
Viruses with RNA Genomes

